SCHEDULE: Balyasny Asset Management Discloses 9.99% Stake in Minerva Neurosciences

Balyasny Asset Management and its affiliates have reported a 9.99% beneficial ownership stake in Minerva Neurosciences, Inc. common stock.

Summary

• Balyasny Asset Management L.P. and its affiliated entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC) and Dmitry Balyasny collectively reported beneficial ownership of 4,330,315 shares of Minerva Neurosciences, Inc. common stock.
• This represents approximately 9.99% of the company's outstanding common stock.
• The ownership percentage is calculated based on 43,274,398 shares outstanding as of December 23, 2025, as reported in Minerva Neurosciences' Form S-3.
• The reported amount includes 4,265,402 shares and 64,913 shares issuable upon the exercise of 13,500 warrants.
• The warrants are subject to a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99% of outstanding shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Minerva Neurosciences.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a reputable institutional investor has taken a significant passive stake, which can be interpreted as a vote of confidence in Minerva Neurosciences.

Positives

• A significant institutional investor, Balyasny Asset Management, has taken a substantial passive stake, potentially signaling confidence in Minerva Neurosciences' long-term prospects.
• The investment is stated to be in the ordinary course of business, indicating a standard portfolio allocation rather than an activist position that could create uncertainty.

Risks

• The beneficial ownership limitation on warrants (9.99%) could restrict Balyasny's ability to increase its stake beyond this threshold through warrant exercise, potentially limiting future upside from this specific instrument if the stock performs well.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance from Minerva Neurosciences. It solely reports a passive beneficial ownership stake by Balyasny Asset Management.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership changes, which can sometimes precede increased market attention or indicate a professional investor's conviction in a company's sector or specific assets. For Minerva Neurosciences, a biopharmaceutical company, attracting a notable institutional investor like Balyasny Asset Management could be viewed positively by the market, especially given the inherent risks and capital intensity of the biotech industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake could increase investor confidence and potentially attract further institutional interest, positively impacting share price stability and liquidity.
• Management: While a passive stake, it signifies external validation of the company's value proposition, potentially bolstering management's strategic direction.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by Balyasny Asset Management, which can be seen as a positive signal of confidence in Minerva Neurosciences. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' recommendation. Investors should 'hold' and monitor future company developments and Balyasny's ongoing position for further insights.

Keywords

Minerva Neurosciences, Balyasny Asset Management, MNVA, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Warrants, SEC Filing, Passive Investment